Carl Borrebaeck received the first chair as professor of Immunotechnology in Scandinavia 1990. His main research interests are cancer proteomics, for early detection and prognosis, and antibody engineering, for the generation of human therapeutic antibodies. He founded CREATE Health Translational Cancer Center 2005, focusing on clinically unmet needs.
He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy, the Research!Sweden Award 2012 for his medical research of value for patients and health organizations, and the Royal Academy of Engineering Sciences Gold Medal 2012 for outstanding contributions to biomedical science.
He is a permanent member of the Royal Swedish Academy of Engineering Sciences. He held the position as the Vice President of Lund University, 20092015, responsible for innovations and industrial collaborations. Professor Borrebaeck spent a sabbatical year at the Oklahoma Medical Research Foundation 1996-97 and did his post-doctoral training at the University of California in Davis. He received his Doctor of Science (D.Sc.) in 1979. His research has resulted in several spin-out companies, such as BioInvent International AB, Alligator Bioscience AB, Immunovia AB, SenzaGen AB and Atlas Therapeutic AB.